openPR Logo
Press release

STEMart Introduces Acute Systemic Toxicity Testing Service for Medical Devices

03-24-2022 09:35 AM CET | Health & Medicine

Press release from: STEMart

STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, now launches Acute Systemic Toxicity testing for the medical device industry. The testing is following the biocompatibility guidelines modified for medical devices.

Biocompatibility is used to describe the appropriate biological requirements for biological materials used in medical devices. Biocompatibility is also described as the ability of a device material to perform with an appropriate host response in a particular application. Biocompatibility assessment is an essential part of the overall safety evaluation of medical devices. Biocompatibility systemic toxicity tests are in vivo systemic tests used to assess systemic damage or activation, not damage to individual cells or organs. Systemic toxicity tests include acute systemic toxicity tests and pyrogenic tests.

Acute toxicity is considered an adverse reaction that occurs after a single or repeated dose of the test article was administered within 24 hours. Acute systemic toxicity tests determine the systemic toxic effects of medical biomaterials following a single acute exposure to the body. Acute systemic testing can provide broad guidance on health hazards that may result from acute exposure to medical devices or chemical materials. When animal test material extracts or liquid chemicals were administered, subsequently, signs of toxicity are observed at 24 ± 2, 48 ± 2 and 72 ± 2 hours.

"Tests for systemic toxicity" is part 11 of the Biological evaluation of medical devices standards(ISO 10993-11) and gives general considerations to be considered when evaluating a medical device for the potential to induce acute systemic toxicity and pyrogenicity. According to the study procedures mentioned in ISO 10993-11 for the assessing of the potential of medical devices and their constituent materials to induce systemic toxicity, STEMart offers various systemic toxicity testing services.

For Test Methods, STEMart offers acute oral toxicity test, acute dermal toxicity test, acute inhalation toxicity test, acute intravenous toxicity test, and acute intraperitoneal toxicity test. For test animals, STEMart prepares mice, rats, or rabbits. As for Test Items, STEMart provides visual observations of animals, routine hematology and serum chemistry tests with blood samples, and microscopic examination with representative tissue samples.

STEMart offers comprehensive biocompatibility testing for in vitro and in vivo evaluation. With extensive expertise in biocompatibility testing, STEMart can provide a full-service experience that supports manufacturers in meeting regulatory goals and minimizing compliance risk.

If you have additional questions about medical device Acute Systemic toxicity testing or if you would like to find out more about the medical device development service, please visit https://www.ste-mart.com.

STEMart
New York, USA
Staci Horme
contact@ste-mart.com

About STEMart

STEMart is an industry-leading eCommerce platform with an expanded global footprint and has a broad portfolio of more than 10,000 products. It aims to provide best-in-class lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage towards the manufacturing process. STEMart is dedicated to making research and biotech production simpler and safer, and through that to accelerate access to better health for people everywhere.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release STEMart Introduces Acute Systemic Toxicity Testing Service for Medical Devices here

News-ID: 2584346 • Views:

More Releases from STEMart

STEMart Introduces Biocompatibility Evaluation of Breathing Gas Pathways in Medi …
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, expands its Biocompatibility Testing services and introduces biocompatibility evaluation of breathing gas pathways in medical devices. This new testing follows the biocompatibility guidelines modified for medical devices and uses a solid scientific rationale. Biocompatibility evaluation of breathing gas pathways in medical devices is a powerful tool for assessing contaminants from the air emitted from
STEMart Introduces Medical Device Testing Services for Research Community
As a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, STEMart recently introduces medical device testing services for researchers all over the world. In accordance with ISO 10992 and ISO 18562 standards, FDA guidance, ASTM (American Society of Testing Materials) standards and other international guidelines, STEMart's experts with years of experience in a variety of testing services for Class, I, II and III

More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth